OKYO Pharma reports long-term shelf stability of corneal pain treatment
Portfolio Pulse from
OKYO Pharma has demonstrated long-term shelf stability of urcosimod, its experimental corneal pain treatment, for over two and a half years in single-use ampoules. The drug maintained over 94% stability under refrigerated conditions, which is a significant step towards potential FDA New Drug Application (NDA) approval.
March 31, 2025 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Long-term stability confirmation for urcosimod represents a critical advancement in OKYO's regulatory strategy for treating neuralgia corneal pain (NCP).
Successful long-term drug stability is a key requirement for FDA approval. This milestone increases OKYO's chances of advancing its NDA, potentially driving investor confidence and stock value.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100